Immunic, Inc.
Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
– Pivotal Phase 3 ENSURE-1 and ENSURE-2 Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Remain on Track, with Top-Line Data Expected…